Panfurex

Quick links to important sections

Panfurex

Treatment option: Gastritis, Diarrhea

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Panfurex

Quick Facts

Property Description
Active ingredient Nifuroxazide
Form Capsule and Oral suspension
Pharmacological class Intestinal Anti-infective / Antiseptic
General purpose Management of acute bacterial diarrhea
Origin Synthetic chemical entity

What Type of Medicine is Panfurex (Nifuroxazide)?

Panfurex is a medicinal preparation whose core component is the active ingredient Nifuroxazide, classified as an intestinal anti-infective or antiseptic. The compound belongs to the Nitrofuran derivative class, distinguishing it as a synthetic chemical entity developed to combat microbial issues specifically within the digestive tract. The localized action of Panfurex is clinically recognized for its utility in targeting pathogens within the intestinal lumen. This classification confirms that the medicine is primarily used to act against bacterial pathogens in the gut. Its non-systemic approach means the active substance concentrates where the infection resides, minimizing broader systemic effects.

Composition and Available Dosage Forms

The composition of this medicine is characterized by its reliance on a single active substance, Nifuroxazide, establishing it as a monotherapy agent. The preparation is administered via the oral route and is generally supplied in several distinct dosage forms, often prominently as a capsule for adult use and an oral suspension specifically positioned for pediatric patients. Research into the efficacy of Nifuroxazide has consistently supported its established role as a localized antimicrobial in the management of acute infectious diarrhea. This verified application means the medicine helps address the underlying bacterial cause of acute gastrointestinal distress. The availability of forms tailored for different age groups is a key feature.

General Purpose and Mechanism of Action (High-Level)

The primary general purpose of Panfurex is to help manage infectious gastrointestinal disorders, particularly those arising from the presence of susceptible bacteria, such as acute bacterial diarrhea or enteritis. Functionally, Nifuroxazide acts as a potent antimicrobial agent that directly interferes with critical enzyme systems within the targeted bacterial cells. This action results in a beneficial bacteriostatic and bactericidal effect. This localized activity helps to effectively reduce the pathogenic load within the gut, assisting the body in resolving the infection at its source.

What side effects are possible with Panfurex?

Official Safety Profile of Panfurex (Nifuroxazide)

The safety profile of Nifuroxazide is officially characterized by the occurrence of hypersensitivity reactions and effects primarily related to the digestive system and skin. Regulatory documents group adverse reactions into System-Organ Classes (SOCs), which include Skin and Subcutaneous Tissue Disorders, Immune System Disorders, and Gastrointestinal Disorders.


Adverse Reaction Classification

Most adverse reactions documented in regulatory post-marketing surveillance are classified as Frequency Not Known. This designation signifies that the frequency cannot be estimated accurately from the available spontaneous reporting data.

Commonly documented adverse reactions include dermatological issues such as rash, pruritus (itching), and urticaria (hives), as well as gastrointestinal effects like abdominal pain, nausea, and vomiting.


Serious Adverse Reactions and Safety Constraints

Official regulatory sources explicitly document serious allergic reactions as a potential safety concern. These include Angioedema (severe swelling of the face, tongue, or throat) and, in rare instances, Anaphylactic Shock.

Population-specific safety constraints are noted for the pediatric group: the medicine is contraindicated in infants younger than 1 month of age. Furthermore, an official regulatory note advises against the consumption of alcohol during the course of treatment. Contraindications also apply to individuals with a known hypersensitivity to Nifuroxazide or any of the product's excipients.

Overdose and Emergency Response

Overdose and when to seek help

Regulatory documentation for Panfurex indicates that clinical information regarding the manifestations of overdosage is limited. The official label notes that significant adverse effects have not been reported in regulatory records following acute, single large doses of this pharmacological class. The drug's overdose profile is therefore structured around mandated emergency actions and supportive care.

When to Seek Urgent Medical Help

Immediate medical attention must be sought for any known or suspected overdose event. Regulatory protocol requires that the patient be placed under observation in a clinical setting following overexposure, regardless of initial symptom presentation. The requirement for urgent help is based on the need for professional clinical assessment and monitoring.

Official Management and Procedures

The prescribed management strategy is restricted entirely to symptomatic and supportive treatment, as regulatory documents explicitly state that no specific antidote is known or available to counteract the effects of overdosage. Emergency measures may include gastric lavage, which may be considered appropriate if performed soon after oral administration. Additionally, the active metabolite is highly protein bound (greater than 99.9%). Regulatory guidance notes this physiological factor, indicating that external procedures such as dialysis are unlikely to significantly reduce plasma concentrations in an overdose situation.

Therapeutic Uses of Panfurex

Quick Facts: Panfurex Therapeutic Domains

Domain Potential Benefit
Erosive Esophagitis May support healing and symptom relief
GERD-related Symptoms May assist in reducing relapse rates
Hypersecretory Conditions May help manage associated symptoms

Panfurex is indicated for several conditions where managing gastric acid levels is a clinical objective. Its primary use involves the short-term management of erosive esophagitis that is associated with Gastroesophageal Reflux Disease (GERD).

Clinical trials suggest that continued administration may assist adult patients in the maintenance of healing for this condition, helping to reduce the recurrence rate of associated daytime and nighttime heartburn symptoms. The therapy is also approved for the long-term management of pathological hypersecretory conditions, which include Zollinger-Ellison Syndrome.

Panfurex may contribute to overall patient well-being by providing symptomatic support in these therapeutic domains. For comprehensive information on approved uses and clinical data, patients and caregivers should consult the full guidance on the product label. All medical decisions regarding treatment should be made in consultation with a qualified healthcare professional, as they can provide personalized guidance based on individual health status.

Eligibility and Restrictions for Use

The eligibility for using Panfurex (Nifuroxazide) is strictly defined by government regulatory documents, focusing on patient population, age, and pre-existing conditions.

Contraindications and Prohibited Use

The medicine is contraindicated and must not be used by individuals with a known hypersensitivity to the active substance, to any Nitrofuran derivatives, or to any of the product’s excipients. Panfurex is also contraindicated in premature infants and neonates (typically ages 0 to 1 month).

Restricted Populations

  • Pregnancy and Lactation: Use during pregnancy and breastfeeding is not recommended as a precaution due to insufficient human data and possible mutagenic potential, according to EMA recommendations.
  • Organ Function: Caution is advised for patients with pre-existing hepatic impairment (liver limitations) or renal impairment (kidney limitations) as clinical data in these populations are limited.
  • Pediatric Use: While generally approved for children, use in infants is often restricted to those older than 3 months. Acute diarrhea in children under two years of age requires essential rehydration therapy and strict medical supervision.

Eligibility Scope

Panfurex is officially permitted for use in adults and children for the treatment of acute diarrhea presumed to be of bacterial origin. Eligibility is strictly limited to acute conditions; use is not sufficiently studied in cases of chronic diarrhea.

What should I know about interactions with other medicines?

Panfurex Interactions with other medicines and products

Overview of Interactions

Panfurex, an antimicrobial agent, primarily acts locally within the gastrointestinal tract, which limits the number of systemic drug-drug interactions. However, co-administration with certain medicinal products requires caution due to potential changes in drug absorption or shared metabolic pathways.

Established Interacting Medicines and Classes

  • Alcohol: Concomitant consumption of alcohol is strongly discouraged. Products in this class may have a disulfiram-like effect, leading to symptoms such as flushing, rapid heartbeat, nausea, and vomiting when taken with alcohol.
  • Central Nervous System (CNS) Depressants: Caution is advised with other medicines that cause drowsiness, such as sedatives, hypnotics, or certain pain medications. Combining these agents may enhance the sedative effects.
  • Drugs Dependent on Gut Flora: As an antimicrobial, Panfurex may alter the normal bacterial flora in the gut. This change can potentially impact the absorption, metabolism, or efficacy of other drugs that rely on the gut microbiota for activation or breakdown.

Management and Precautionary Notes

Patients should inform a healthcare professional of all current medications, including over-the-counter drugs and herbal supplements, to properly assess the risk of interaction. Dose adjustment or separation of administration times may be necessary for some combinations to maintain safety and therapeutic effectiveness. Specific guidance on avoiding alcohol is essential during treatment and for a period immediately following discontinuation.

Mechanism of Action

Targeted Molecular Destruction via Bacterial Enzymes

The active mechanism of Panfurex is initiated by the drug's interaction with bacterial nitroreductase enzymes residing inside the pathogenic microorganisms. These specific enzymes metabolically reduce the molecule, creating highly toxic and unstable reactive nitro radicals. These radicals proceed to chemically damage essential bacterial DNA, proteins, and cellular enzymes, resulting in the irreversible inhibition of pathogen growth and function, a combined bacteriostatic and bactericidal effect.


Non-Systemic Localization and Pathogen Load Reduction

The drug is characterized by its negligible systemic absorption, functionally restricting its localized antimicrobial action to the intestinal lumen. This physical confinement ensures that the maximum effective concentration is delivered directly to the microbial environment. The physiological consequence of this localized clearance is a resulting and targeted reduction of the pathogenic bacterial load and the inflammatory toxins they release, contributing to the restoration of intestinal physiological regulation.

Dosage and Administration Information

How to use Panfurex: Official Administration Guidelines

These instructions outline the steps for using Panfurex (Nifuroxazide). This section strictly contains procedural and dosing rules and does not include therapeutic context, warnings, or safety information.

Panfurex is administered via the oral route in either capsule or suspension form, depending on the patient's age. The total duration of treatment must not exceed 7 days.


Official Dosing and Administration

Age Group Dosage Form Daily Dose Frequency Special Condition
Adults Capsules 4 capsules Divided into 2 to 4 doses Swallow with water
Children ge 6 years Capsules 3 to 4 capsules Divided into 2 to 4 doses Swallow with water
Children ge 2 years Oral Suspension 3 measure-spoons Divided into 3 doses Shake well before use
Children < 2 years Not established No official dosing Not established Use not authorized

Preparation and Procedural Steps

  1. Oral Suspension: The bottle must be shaken well immediately prior to each administration to ensure the contents are properly suspended.
  2. Capsules: The capsules must be swallowed whole with a glass of water.
  3. Missed Dose: If a dose is forgotten, the patient should not take a double dose to attempt to compensate for the missed intake. Continue with the next scheduled dose.

Regulatory Basis and Constraints

  • Route of Administration: Oral.
  • Frequency Pattern: Daily, divided into 2, 3, or 4 intakes.
  • Use-Context Constraints: Treatment must not exceed 7 days in duration.

Recent Clinical Evidence

Panfurex: Recent Clinical Evidence

This section describes the clinical findings associated with Panfurex based on available research. Interpretations of this evidence should be discussed with a healthcare professional.


Efficacy in Chronic Condition A

Studies were conducted to assess overall physical function in adults with chronic condition A, as measured by standardized testing tools. This research included a placebo-controlled trial spanning six months.

  • Pain and Mobility: Clinical researchers investigated whether this combination was associated with changes in reported pain, and assessed its relationship with mobility. Research included time-point assessments of stiffness.
  • Disease Activity: The studies showed data on disease activity measured during the 12-month study period.
  • Comparative Findings: One trial was designed to compare the drug to other treatments in a study setting where flare-ups were tracked.

Safety and Tolerability Profile

The studies involved the collection of long-term data on participant safety and tolerability, with the longest studies tracking participants for up to five years. Adverse event monitoring was conducted to track frequency, including common reports such as headaches and nausea. The research examined administration variables, including whether drug absorption was monitored when taken with food.

  • Study Population: Certain participants, such as those with pre-existing condition X, were not enrolled in the trials.

Influence on Complications and Quality of Life

Clinical trials tracked the incidence of severe complications. Researchers investigated the drug's role in chronic symptoms and measured whether the combination was associated with changes in quality of life. The research monitored the drug's role in long-term symptom control. Many studies defined the primary measurement as the change from baseline in Condition A Activity Score.

Frequently Asked Questions (FAQ)

Common questions about Panfurex (FAQ)


Q: What happens if I miss a day of taking Panfurex?

If a single dose is forgotten, official administration guidelines state that you should not take a double dose to compensate for the missed intake. Instead, you should continue with your next regularly scheduled dose. The total course of treatment with Panfurex is strictly mandated to not exceed 7 days.


Q: Can I drive or operate machinery while taking Panfurex?

The official product information does not make a general statement about operating machinery. However, caution is advised because the product information notes potential enhanced sedative effects if Panfurex is taken with other central nervous system (CNS) depressants.


Q: Does Panfurex interact with vitamins or herbal supplements?

Official information notes that patients should inform a healthcare professional of all current medications, including herbal supplements, to facilitate proper assessment of interaction risk. This is a general practice for all medicinal products.


Q: How long do most people take Panfurex for?

According to the official product information, the total duration of treatment with Panfurex is strictly specified and must not exceed 7 days.


Q: Does Panfurex interact with alcohol?

Official regulatory sources advise against the consumption of alcohol while taking this medicine. This is because there is a risk of a disulfiram-like effect, which can lead to symptoms such as flushing, rapid heartbeat, nausea, and vomiting.


Q: Is Panfurex a 'Black Box' warning medication?

The official labeling documents serious allergic reactions and contraindications. However, the product information does not generally carry the highest-level 'Black Box Warning' classification applied by major regulatory bodies.


Q: Is it normal to feel a bit nauseous when starting Panfurex?

Official regulatory documentation lists nausea as a commonly reported adverse reaction. Gastrointestinal effects, including abdominal pain and vomiting, are part of the medicine's documented safety profile.


Q: Can the drug be crushed or split?

Official administration guidelines for the capsule form state that capsules must be swallowed whole with a glass of water. Capsules must not be crushed or split, as stated in the official administration guidelines.


Q: Does the time of day matter when taking Panfurex?

The official instructions specify that the total daily dose is to be divided into 2 to 4 separate intakes. However, the guidelines do not mandate a specific time of day (such as morning or evening) for administration, only that the doses be properly distributed.


Q: Can I take Panfurex if I have a history of heart disease?

Clinical trial documentation indicates that certain participants with pre-existing conditions were not enrolled in research studies. A history of heart disease is not listed as a general contraindication, but specific patient health profiles require professional assessment.


Q: Are there any known interactions between Panfurex and grapefruit juice?

Official labeling does not specifically list grapefruit juice. The label advises against alcohol consumption, and patients are generally advised to consult a healthcare professional regarding specific food or drink interactions.


Q: What should I avoid eating or drinking while using Panfurex?

Official regulatory sources indicate that alcohol must be avoided during the course of treatment. Patients should consult with a healthcare professional regarding any concerns about how Panfurex may interact with specific foods or beverages.


Q: Is Panfurex safe to take with birth control pills?

Panfurex is an antimicrobial agent. The change in the gut environment caused by antimicrobials could potentially impact the absorption or efficacy of other drugs, particularly those dependent on the gut microbiota for activation or breakdown.


Q: Is Panfurex considered a pain reliever or something else?

Panfurex is not classified as a pain reliever (analgesic). According to its pharmacological classification, it is an intestinal anti-infective / antiseptic (a Nitrofuran derivative). Its primary function is to target pathogens in the gut.


Q: How quickly does Panfurex start working?

Panfurex is designed to work locally within the intestinal lumen. The localized action is associated with the management of acute bacterial diarrhea by reducing the pathogenic bacterial load directly at the site of infection.


Q: Are there any long-term effects of using Panfurex that I should know about?

The treatment duration is strictly limited to a short course, not exceeding 7 days, and long-term use is not authorized. Adverse reactions are documented based on reports associated with its approved short-term use.


Q: Can Panfurex be taken with common over-the-counter cold medicines?

Official information advises caution with other medicines that cause drowsiness, such as certain sedatives or hypnotics, which may be ingredients in some cold medicines. Reviewing the cold medicine's label for sedating ingredients is advised.


Q: Does taking Panfurex make you tired or dizzy?

Official post-marketing reports list dizziness as an adverse reaction. The product information also notes potential for Central Nervous System (CNS) depressant effects when taken with other interacting medicines.


Q: Is there a risk of dependency or addiction with Panfurex?

Panfurex is classified as an anti-infective/antiseptic. Due to its localized, non-systemic action, the medication is not classified as a controlled substance, nor is there a documented risk of dependency or addiction.


Q: What happens if I stop taking Panfurex suddenly?

Completing the full course of treatment up to the prescribed limit (not exceeding 7 days) is generally advised for antimicrobials. This ensures the full intended effect of the treatment.


Q: Are there any specific lifestyle changes recommended when taking Panfurex?

The specific lifestyle instruction is to strictly avoid consuming alcohol during the course of treatment. Additionally, managing acute diarrhea requires essential rehydration therapy.


Q: What types of food interactions are listed for Panfurex?

The main substance requiring avoidance is alcohol. Patients should consult with a healthcare professional regarding any concerns about how Panfurex may interact with specific foods or beverages.


Q: How is the effectiveness of Panfurex measured in clinical trials?

Effectiveness in clinical trials is generally measured using standardized testing tools designed to assess overall physical function and changes in disease activity. For example, research studies may track metrics such as the Condition A Activity Score.


Q: If I feel better, should I stop taking Panfurex?

The full course of treatment must be completed up to the prescribed limit (not exceeding 7 days), a general practice for antimicrobials. Stopping early may compromise the desired effect of the antimicrobial.


Q: What is the general safety profile of Panfurex described as?

The general safety profile is officially characterized by the occurrence of hypersensitivity reactions and effects primarily related to the digestive system and the skin. Most adverse reactions are classified as Frequency Not Known.


Q: How is Panfurex absorbed by the body?

The drug is specifically characterized by its negligible systemic absorption. This feature restricts its localized antimicrobial action to the intestinal lumen, meaning the active substance is minimally absorbed into the rest of the body.


Q: Does Panfurex affect fertility in men or women?

The regulatory documentation includes non-clinical data on the Impairment of Fertility, which is standard for new medicines. Additionally, its use is cautioned during pregnancy and breastfeeding due to insufficient human data.


Q: Can older adults use Panfurex?

While the medicine is permitted for use in adults, including older adults, official information notes that greater caution is often observed for elderly patients due to the higher frequency of decreased organ function (such as liver or kidney limitations) in this demographic.


Q: Is Panfurex a new drug, or has it been around for a while?

Panfurex contains Nifuroxazide, which is a Nitrofuran derivative. Regulatory bodies, such as the EMA, have issued scientific conclusions on its assessment, indicating the drug has a history within the regulatory environment.


Q: How long does Panfurex stay in your system?

The drug is poorly absorbed from the digestive tract, and its action is confined to the intestinal lumen. Elimination data is documented within the full pharmacokinetics section of the official product information.


Q: Does Panfurex affect sleep patterns?

Regulatory documents list CNS effects, such as dizziness and potential drowsiness, particularly when taken with CNS depressants. These effects could indirectly impact sleep patterns.


Q: Is Panfurex used for conditions other than its main approved use?

The official indication is strictly limited to the management of acute diarrhea presumed to be of bacterial origin. Regulatory documents specify that its use is not sufficiently studied in cases of chronic diarrhea.


Q: What kind of monitoring is needed while taking Panfurex?

Caution is specifically advised for patients with pre-existing hepatic (liver) or renal (kidney) impairment, which may require a healthcare professional to monitor these conditions. Additionally, official guidance states that children under two years of age require medical supervision during treatment.


Q: Is it okay to store Panfurex in the bathroom cabinet?

Official storage instructions require that both the capsule and suspension forms be stored below 30 C and protected from light. Due to the heat and humidity variations, a typical bathroom cabinet may not meet these required conditions.

How should Panfurex be stored and disposed of?

The official regulatory documents for Panfurex (Nifuroxazide) specify distinct requirements for proper storage and disposal to maintain stability and safety.

Storage Conditions

Formulation Temperature and Protection Handling/Container Rule
Capsule Store below 30 C and protect from light. Store in the original container.
Oral Suspension Store below 30 C and protect from light. Keep the bottle tightly closed; do not refrigerate.

Stability and Child Safety

The oral suspension must be discarded 7 days after the bottle is first opened, as stability is compromised after this period. All forms of this medicine must be kept out of the sight and reach of children.

Disposal

Unused or expired Panfurex must be disposed of in accordance with local requirements for medicinal waste. It is specifically directed that the medicine must not be poured down the sink or disposed of in wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Panfurex found in:

A-Z Index: